RxDoctor Payments DataLook up a doctor →

Crystal Keeton

Family · Florence, ALNPI 1356889273

Payments from drug & device makers

$13,642in general payments, 2019–2025

Across 648 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novartis$2K
  • Johnson & Johnson$782
  • Merck$624
  • Lilly USA, LLC$600
  • Incyte Corporation$582
  • plus $7K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)100$2,220
Novartis91$1,551
Johnson & Johnson28$782
Merck30$624
Lilly USA, LLC32$600
Incyte Corporation24$582
Bristol Myers Squibb26$508
Pfizer31$490
Sanofi16$363
Amgen20$353
Seagen Inc.15$308
Genentech USA, Inc.15$306
Sobi, Inc9$264
Takeda Pharmaceuticals U.S.A., Inc.10$229
Jazz Pharmaceuticals Inc.11$222
GSK8$221
Array Biopharma Inc11$219
Eisai Inc.11$199
Daiichi Sankyo Inc.9$195
Stemline Therapeutics Inc.7$192
Astellas Pharma US Inc3$192
Pharmaessentia USA Corporation8$189
Bayer8$163
Beigene USA, Inc.9$160
Regeneron Healthcare Solutions, Inc.9$147
Deciphera Pharmaceuticals Inc.6$131
Gilead(2 entities)8$130
Phathom Pharmaceuticals, Inc.1$127
Servier Pharmaceuticals LLC5$120
Pharmacosmos Therapeutics Inc.3$111
Boehringer Ingelheim5$110
Beone Medicines USA, Inc.6$110
AbbVie5$109
Sumitomo Pharma America, Inc.5$107
Exelixis Inc.4$98
Shield Therapeutics Inc4$97
Pharmacyclics LLC, An Abbvie Company6$97
Rigel Pharmaceuticals, Inc.5$88
E.r. Squibb & Sons, L.L.C.4$77
EMD Serono, Inc.3$72
Karyopharm Therapeutics Inc.4$70
Adaptive Biotechnologies Corporation3$64
ADC Therapeutics America, Inc.3$61
Sun Pharmaceutical Industries Inc.2$59
Myriad Genetic Laboratories, Inc.3$45
AVEO Pharmaceuticals, Inc.2$45
Coherus Oncology, Inc.2$44
Ipsen Biopharmaceuticals, Inc2$41
Tersera Therapeutics LLC2$41
Blueprint Medicines Corporation2$37
Procept Biorobotics Corporation1$37
Dendreon Pharmaceuticals LLC1$31
Spectrum Pharmaceuticals Inc.1$28
Dova Pharmaceuticals1$24
Recordati_rare_diseases_inc.1$24
Fennec Pharmaceuticals, Inc.1$23
Kedrion Biopharma, Inc.1$23
Kyowa Kirin, Inc.1$20
Novocure Inc.1$16
Taiho Oncology, Inc.1$16

How this compares

$13,642 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$90,580
Medicare patients
170
Services billed
4,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →